Granted Patent
B2
US 12,351,648 · App. 17/194,054 · Granted Jul 8, 2025
Methods of inhibiting MASP-2 for the treatment and/or prevention of coronavirus-induced acute respiratory distress syndrome
Assignee:
Omeros Corporation
View Patent ↗
Loading inventors, assignments & file history…
Abstract
In one aspect, the invention provides methods for treating, inhibiting, alleviating, or preventing acute respiratory distress syndrome, pneumonia, or some other pulmonary or other manifestation of coronavirus infection, such as thrombosis, in a mammalian subject infected with coronavirus, such as SARS-CoV-2. The methods comprise the step of administering to a subject infected with coronavirus an amount of a MASP-2 inhibitory agent effective to inhibit MASP-2-dependent complement activation. In one embodiment, the MASP-2 inhibitory agent is a MASP-2 monoclonal antibody, or fragment thereof that specifically binds to a portion of SEQ ID NO:6. In one embodiment, the MASP-2 inhibitory agent is a small molecule MASP-2 inhibitory compound. In one embodiment, the subject is a human subject suffering from COVID-19-induced acute respiratory distress syndrome (ARDS) and requires supplemental oxygen prior to treatment and the MASP-2 inhibitory agent is administered in an amount sufficient to discontinue the need for supplemental oxygen.
Claims (6)
1. A method for improving respiratory function in a human subject suffering from COVID-19 induced acute respiratory distress syndrome (ARDS) wherein said subject requires mechanical ventilation, comprising administering to the subject an amount of a MASP-2 inhibitory monoclonal antibody or antigen-binding fragment thereof and for a time period sufficient to discontinue the need for mechanical ventilation, wherein the MASP-2 inhibitory monoclonal antibody or antigen-binding fragment thereof comprises a heavy chain variable region comprising CDR-H1, CDR-H2 and CDR-H3 of the amino acid sequence set forth as SEQ ID NO:67 and a light chain variable region comprising CDR-L1, CDR-L2 and CDR-L3 of the amino acid sequence set forth as SEQ ID NO:69.
2. The method of claim 1 , wherein the subject requires supplemental oxygen prior to treatment and the MASP-2 inhibitory monoclonal antibody or antigen-binding fragment thereof is administered at a dosage and for a time period sufficient to discontinue the use of supplemental oxygen.
3. The method of claim 1 , wherein the antibody or fragment thereof is selected from the group consisting of a recombinant antibody, an antibody having reduced effector function, a chimeric antibody, a humanized antibody and a human antibody.
4. The method of claim 1 , wherein the MASP-2 inhibitory antibody selectively inhibits lectin pathway complement activation without substantially inhibiting C1q-dependent complement activation.
5. The method of claim 1 , wherein the MASP-2 inhibitory antibody inhibits C3b deposition in 10% human serum with an IC 50 of 30 nM or less.
6. The method of claim 1 wherein the MASP-2 inhibitory antibody or antigen-binding fragment thereof comprises a heavy chain variable region comprising SEQ ID NO:67 and a light chain variable region comprising SEQ ID NO:69.
Assignments (4)
RELEASE OF SECURITY INTEREST
Recorded Nov 25, 2025
From: WILMINGTON SAVINGS FUND SOCIETY, FSB
To: OMEROS CORPORATION
Reel/Frame 073705/0970 →
CORRECTIVE ASSIGNMENT TO CORRECT THE CORRECT THE BOX TITLED"THIS DOCUMENT SERVES AS AN OATH/DECLARATION (37 CFR 1.63)" WAS ERRONEOUSLY CHECKED AND THIS BOX SHOULD NOT HAVE BEEN CHECKED, PREVIOUSLY RECORDED AT REEL: 67607 FRAME: 108. ASSIGNOR(S) HEREBY CONFIRMS THE SECURITY INTEREST.
Recorded Dec 11, 2024
From: OMEROS CORPORATION
To: WILMINGTON SAVINGS FUND SOCIETY, FSB, AS COLLATERAL AGENT
Reel/Frame 069715/0719 →
SECURITY INTEREST
Recorded Jun 3, 2024
From: OMEROS CORPORATION
To: WILMINGTON SAVINGS FUND SOCIETY, FSB, AS COLLATERAL AGENT
Reel/Frame 067607/0108 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Jul 12, 2022
From: DEMOPULOS, GREGORY A.; QUINTON, TINEKA J.
To: OMEROS CORPORATION
Reel/Frame 060487/0665 →
Continuity (9)
Provisional Application
62986566
· Mar 6, 2020
Provisional Application
63008540
· Apr 10, 2020
Provisional Application
63015299
· Apr 24, 2020
Provisional Application
63054298
· Jul 21, 2020
Provisional Application
63062843
· Aug 7, 2020
Provisional Application
63104229
· Oct 22, 2020
Provisional Application
63105637
· Oct 26, 2020
Provisional Application
63140591
· Jan 22, 2021
References Cited (285)
US 4331647A
· Goldenberg
· 1982
[cited by applicant]
US 4816567A
· Cabilly et al.
· 1989
[cited by applicant]
US 4946778A
· Ladner et al.
· 1990
[cited by applicant]
US 5211657A
· Yamada et al.
· 1993
[cited by applicant]
US 5223409A
· Ladner et al.
· 1993
[cited by applicant]
US 5403484A
· Ladner et al.
· 1995
[cited by applicant]
US 5552157A
· Yagi et al.
· 1996
[cited by applicant]
US 5565213A
· Nakamori et al.
· 1996
[cited by applicant]
US 5567434A
· Szoka, Jr.
· 1996
[cited by applicant]
US 5571698A
· Ladner et al.
· 1996
[cited by applicant]
US 5610288A
· Rubenstein
· 1997
[cited by applicant]
US 5693762A
· Queen et al.
· 1997
[cited by applicant]
US 5718709A
· Considine et al.
· 1998
[cited by applicant]
US 5738868A
· Shinkarenko
· 1998
[cited by applicant]
US 5739119A
· Galli et al.
· 1998
[cited by applicant]
US 5741516A
· Webb et al.
· 1998
[cited by applicant]
US 5759829A
· Shewmaker et al.
· 1998
[cited by applicant]
US 5789573A
· Baker et al.
· 1998
[cited by applicant]
US 5795587A
· Gao et al.
· 1998
[cited by applicant]
US 5801154A
· Baracchini et al.
· 1998
[cited by applicant]
US 6649592B1
· Larson
· 2003
[cited by applicant]
US 20020019369A1
· Li et al.
· 2002
[cited by applicant]
US 20130344073A1
· Schwaeble et al.
· 2013
[cited by applicant]
US 20160058850A1
· Igonin et al.
· 2016
[cited by applicant]
US 20190127484A1
· Schwaeble et al.
· 2019
[cited by applicant]
CN 104717975A
· 2015
[cited by applicant]
CN 112237630A
· 2021
[cited by examiner]
EP 0321201A2
· 1989
[cited by applicant]
WO WO8804300
· 1988
[cited by applicant]
WO WO9111465
· 1991
[cited by applicant]
WO WO2004009664A2
· 2004
[cited by applicant]
WO WO2004106384A1
· 2004
[cited by applicant]
WO WO2005123128A2
· 2005
[cited by examiner]
WO WO2012151481A1
· 2012
[cited by applicant]
WO WO2013192240A2
· 2013
[cited by applicant]
WO WO2014144542A2
· 2014
[cited by applicant]
WO WO2019231933A2
· 2019
[cited by applicant]
WO WO2019231933A3
· 2019
[cited by applicant]
WO WO2019231935
· 2019
[cited by applicant]
WO WO2019246367A1
· 2019
[cited by applicant]
WO WO2021113682A1
· 2021
[cited by applicant]
WO WO2021113686A1
· 2021
[cited by applicant]
WO WO2021113690A1
· 2021
[cited by applicant]
WO WO2021113698A1
· 2021
[cited by applicant]
Huang et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China,. The Lancet 395(10223) p. 497-506, published Jan. 2020) (Year: 2020).
[cited by examiner]
World Health Organization (WHO): WHO advice for international travel and trade in relation to the outbreak of pneumonia caused by a new coronavirus in China. pp. 1-3, Jan. 10, 2020. (Year: 2020).
[cited by examiner]
Ian M Mackay. Viral pneumonia cluster in Wuhan, centralChina: 44 cases and counting. Virology Down Under, pp. 1-8, Jan. 3, 2020. (Year: 2020).
[cited by examiner]
Yang et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir Med, Feb. 2020, 8:475-81. (Year: 2020).
[cited by examiner]
Chen, C., et al., “Stoichiometry of Complexes between Mannose—binding Protein and Its Associated Serine Proteases,”
[cited by applicant]
Feinberg, H., et al., “Crystal structure of the CUB1-EGF-CUB2 region of mannose-binding protein associated serine protease-2,”
[cited by applicant]
Stover, C.M., et al., “The rat and mouse homologues of MASP-2 and Map19, components of the lectin activation pathway of complement,”
[cited by applicant]
Thiel, S., et al., “A second serine protease associated with mannan-binding lectin that activates complement,”
[cited by applicant]
Thielens, N.M., et al., “Interaction Properties of Human Mannan-Binding Lectin (MBL)-Associated Serine Proteases-1 and -2, MBL-Associated Protein 19, and MBL,”
[cited by applicant]
Matsushita, M., et al., “Cutting Edge: Complement-Activatting Complex of Ficolin and Mannose-Binding Lectin-Associated Serine Protease,”
[cited by applicant]
Rodrigues, M.L., et al., “Engineering Fab' Fragments for Efficient F(ab)
[cited by applicant]
Riedemann, N.C., et al., “Complement in Ischemia Reperfusion Injury,”
[cited by applicant]
Matsushita, M. et al., “Activation of the Lectin Complement Pathway by H-Ficolin (Hakata Antigen),”
[cited by applicant]
Stengaard-Pedersen, K., et al., “Inherited Deficiency of Mannan-Binding Lectin-Associated Serine Protease 2,”
[cited by applicant]
Moller-Kristensen, M., et al., “Levels of mannan-binding lectin-associated serine protease-2 in healthy individuals,”
[cited by applicant]
Petersen, S.V., et al., “Control of the Classical and MBL Pathway of Complement Activation,”
[cited by applicant]
Petersen, S.V., et al., “An assay for the mannan-binding lectin pathway of complement activation,”
[cited by applicant]
Liszewski, M. Kathryn and Atkinson, John P., The Complement System, Chapter 26, pp. 917-939.
[cited by applicant]
Collard, C.D., et al., “Complement Activation after Oxidative Stress: Role of the Lectin Complement Pathway,”
[cited by applicant]
Jordan, J.E., et al., “Inhibition of Mannose-Binding Lectin Reduces Postischemic Myocardial Reperfusion Injury,”
[cited by applicant]
Collard, C.D., et al., “Endothelial Oxidative Stress Activates the Lectin Complement Pathway,”
[cited by applicant]
Kilpatrick, D.C., “Mannan-binding lectin: clinical significance and applications,”
[cited by applicant]
Kalli, K., et al., “Therapeutic Uses of Recombinant Complement Protein Inhibitors,” Springer Seminars in Immunopathology 15(4):417-431 (1994).
[cited by applicant]
Wallis, R., et al., “Localization of the Serine Protease-binding Sites in the Collagen-like Domain of Mannose-binding Protein,”
[cited by applicant]
Wallis, R., et al., “Interaction of Mannose-binding Protein with Associated Serine Proteases: Effects of Naturally Occurring Mutations,”
[cited by applicant]
Petersen, S.V., et al., “Generation of Antibodies Towards MASP-1 and MASP-2 Using Bacterial Expression Systems,”
[cited by applicant]
Cech, T.R., et al., “Biological Catalysis by RNA,”
[cited by applicant]
Clackson, T., et al., “Making antibody fragments using phage display libraries,”
[cited by applicant]
Chen, P.-F., et al., “Development of the Non-palindromatic Adaptor Polymerase Chain Reaction (NPA-PCR) for the Amplification of Alpha- and Beta-Chain T-Cell Receptor of cDNAs.”
[cited by applicant]
Bird, R.E., et al., “Single-Chain Antigen-Binding Proteins,”
[cited by applicant]
Climie, S., et al., “Chemical synthesis of the thymidylate synthase gene,”
[cited by applicant]
Carter, P., et al., “Humanization of an anti-p185
[cited by applicant]
Altschul, S.F., et al., “Gapped Blast and PSI-Blast: a new generation of protein database search programs,”
[cited by applicant]
Makino, K., et al., “A Microcapsule Self-Regulating Delivery System for Insulin,”
[cited by applicant]
Lee, V.H.L., “Protease Inhibitors and Penetration Enhancers as Approaches to Modify Peptide Absorption,”
[cited by applicant]
Jolliffe, L.K., et al., “Humanized Antibodies: Enhancing Therapeutic Utility Through Antibody Engineering,”
[cited by applicant]
Jackson, D.Y., et al., “Potent α4β1 Peptide Antagonists as Potential Anti-Inflammatory Agents,”
[cited by applicant]
Hori, R., et al., “Enhanced Bioavailability of Subcutaneously Injected Insulin Coadministered with Collagen in Rats and Humans,”
[cited by applicant]
Satomura, A., et al., “Significant Elevations in Serum Mannose-Binding Lectin Levels in Patients with Chromic Renal Failure,”
[cited by applicant]
Greenspan, N.S., et al., “Idiotypes: structure and immunogenicity,”
[cited by applicant]
De Boer, A.G., et al., “Rectal Absorption Enhancement of Peptide Drugs,”
[cited by applicant]
Fuertges, R., et al., “The Clinical Efficacy of Poly(ethylene glycol)-Modified Proteins,”
[cited by applicant]
Riechmann, L., et al., “Reshaping human antibodies for therapy,”
[cited by applicant]
Singer, I.I., et al., “Optimal Humanization of 1B4, an Anti-CD18 Murine Monoclonal Antibody, Is Achieved by Correct Choice of Human V-Region Framework Sequences,”
[cited by applicant]
Sandhu, J.S., et al., “Protein Engineering of Antibodies,”
[cited by applicant]
Ravetch, J.V., et al., “Fc Receptors,”
[cited by applicant]
Rosenblatt, J., et al., “The Effect of Collagen Fiber Size Distribution on the Release Rate of Proteins from Collagen Matrices by Diffusion,”
[cited by applicant]
Porter, R.R., “The Hydrolysis of Rabbit γ-Globulin and Antibodies with Crystalline Papain,”
[cited by applicant]
Merrifield, R.B., “Solid Phase Peptide Synthesis. I. The Synthesis of a Tetrapeptide,”
[cited by applicant]
Presta, L.G., “Antibody engineering,”
[cited by applicant]
Lee, V.H.L., “Enzymatic Barriers to Peptide and Protein Absorption,”
[cited by applicant]
Yamakawa, I., et al., “Sustained Release of Insulin by Double-Layered Implant Using Poly(D,L-Lactic Acid),”
[cited by applicant]
Ohman, E.M., et al., “Early clinical experience with integrelin, and inhibitor of the platelet glycoprotein IIb/IIIa integrin receptor,”
[cited by applicant]
Pack, P., et al., “Improved Bivalent Miniantibodies, with Identical Avidity as Whole Antibodies, Produced by High Cell Density Fermentation of
[cited by applicant]
Zhang, L., et al., “A Discrete Site Modulates Activation of I Domains: Application to Integrin α
[cited by applicant]
Taylor, L.D., et al., “Human immunoglobulin transgenes undergo rearrangement, somatic mutation and class switching in mice that lack endogenous IgM,”
[cited by applicant]
Takakura, Y. et al., “Control of Pharmaceutical Properties of Soybean Trypsin Inhibitor by Conjugation with Dextran I: Synthsis and Characterization,”
[cited by applicant]
Takakura, Y., et al., “Control of Pharmaceutical Properties of Soybean Trypsin Inhibitor by Conjugation with Dextran II: Biopharmaceutical and Pharmacological Properties,”
[cited by applicant]
Van de Winkel, J.G.J., et al., “Human IgG Fc receptor heterogeneity: molecular aspects and clinical implications,”
[cited by applicant]
Vaughan, T.J., et al., “Human antibodies by design,”
[cited by applicant]
Scatchard, G., “The Attractions of Proteins for Small Molecules and Ions,”
[cited by applicant]
Green, L.L., et al., “Antigen-specific human monoclonal antibodies from mice engineered with human Ig heavy and light chain YACs,”
[cited by applicant]
Glover, G.I., et al., “Synthetic Peptide Inhibitors of Complement Serine Proteases—I. Identification of Functionally Equivalent Protease Inhibitor Sequences in Serpins and Inhibition of C1s and D,”
[cited by applicant]
Fedor, M.J., et al., “Substrate sequence effects on “hammerhead” RNA catalytic efficiency,”
[cited by applicant]
Duncan, A.R., et al., “The binding site for C1q and IgG,”
[cited by applicant]
Dodds, A.W., et al., “Small-Scale Preparation of Complement Components C3 and C4,”
[cited by applicant]
Haseloff, J. et al., “Simple RNA enzymes with new and highly specific endoribonuclease activities,”
[cited by applicant]
Matsushita, M., et al., “Activation of the Classical Complement Pathway by Mannose-binding Protein in Association with a Novel C1s-like Serine Protease,”
[cited by applicant]
Itakura, K. et al., “Synthesis and Use of Synthetic Oligonucleotides,”
[cited by applicant]
Kuntz, I.D., “Structure-Based Strategies for Drug Design and Discovery,”
[cited by applicant]
Ikeda, K., et al., “Serum Lectin with Known Structure Activates Complement through the Classical Pathway,”
[cited by applicant]
Lloyd, B.H., et al., “Determination of optimal sites of antisense oligonucleotide cleavage within TNFα mRNA,”
[cited by applicant]
DesJarlais, R.L., et al., “Structure-based design of nonpeptide inhibitors specific for the human immunodeficiency virus 1 protease,”
[cited by applicant]
Bae, Y.H., et al., “Insulin Permeation Through Thermo-Sensitive Hydrogels,”
[cited by applicant]
Asano, M. et al., “In Vivo Characteristics of Low Molecular Weight Copoly(
[cited by applicant]
Köhler, G., et al., “Continuous cultures of fused cells secreting antibody of predefined specificity,”
[cited by applicant]
Levy, M., et al., “H deficiency in two brothers with atypical dense intramembranous deposit disease,”
[cited by applicant]
Kuntz, I.D., et al., “A Geometric Approach to Macromolecule-Ligand Interactions,”
[cited by applicant]
Marks, J.D., et al., “By-passing Immunization: Human Antibodies from V-gene Libraries Displayed on Phage,”
[cited by applicant]
Murayama, O., et al., “Novel Peptide Ligands for Integrin α6β1 Selected from a Phage Display Library,”
[cited by applicant]
Nisonoff, A., et al., “Separation of Univalent Fragments from the Bivalent Rabbit Antibody Molecule by Reduction of Disulfide Bonds,”
[cited by applicant]
Scherr, M., et al., “Rapid determination and quantitation of the accessibility to native RNAs by antisense oligodeoxynucleotides in murine cell extracts,”
[cited by applicant]
Isaacs, J.D., et al., “Therapy with Monoclonal Antibodies: An in Vivo Model for the Assessment of Therapeutic Potential,”
[cited by applicant]
Whitlow, M., et al., “Single-Chain Fv Proteins and their Fusion Proteins,”
[cited by applicant]
Larrick, J.W., et al., “PCR Amplification of Antibody Genes,”
[cited by applicant]
Jones, P.T., et al., “Replacing the complementarity-determining regions in a human antibody with those from a mouse,”
[cited by applicant]
Ward, E.S., et al., “Genetic Manipulation and Expression of Antibodies,”
[cited by applicant]
Courtenay-Luck, N.S., “Genetic manipulation of monoclonal antibodies,”
[cited by applicant]
Kelley, R.F., “Engineering Therapeutic Antibodies,”
[cited by applicant]
Baines, M.G., et al., “Purification of Immunoglobulin G (IgG),”
[cited by applicant]
Green, J.A., et al., “Production of Polyclonal Antisera,”
[cited by applicant]
Hovind, P., et al., “Mannone-binding Lectin as a Predictor of Microalbuminuria in Type 1 Diabetes: An Inception Cohort Study,”
[cited by applicant]
Harlow, E., et al., “Antibodies: a laboratory manual,” Cold springs Harbor Laboratory, Cold Springs Harbor, New York, 1988. pp. 567-569.
[cited by applicant]
Krarup, A., et al., “Simultaneous activation of complement and coagulation by MBL-associated serine protease 2,”
[cited by applicant]
Schwaeble, H-W., et al. “Targeting of mannan-binding lectin-ssociated serine protease-2 confers protection from myocardial and gastrointestinal ischemia/reperfusion injury,”
[cited by applicant]
Olesen, H.V., et al., “The mannan-binding lectin pathway and lung disease in systic fibrosis-dysfunction of mannan=binding lectin-associated serine protease 2 (MASP-2) may be a major modifier,”
[cited by applicant]
Endo, M., et al., “Glomerular deposition of mannose-binding lectin (MBL) ndicates a novel mechanism of complement activation in IgA nephropathy,”
[cited by applicant]
Hisano, S., et al., “Activation of the lectin complement pathway in Henoch-Schonlein purpura nephritis,”
[cited by applicant]
Roos, A., et al., “Glomerular activation of the lectin pathway of complement in IgA nephropathy is associated with more severe renal disease,”
[cited by applicant]
Lhotta, K., et al., “Glomerular deposition of mannose-binding lectin in human glomerulonephritis,”
[cited by applicant]
Heja, D., et al., “Monospecific Inhibitors Show That Both Mannan-binding Lectin-associated Serine Protease-1 (MASP-1) and -2 Are Essential for Lectin Pathway Activation and Reveal Structural Plasticity of MASP-2,”
[cited by applicant]
Kaufman, R.J., et al., “Improved vectors for stable expression of foreign genes in mammalian cells by use of the untranslated leader sequence from EMC virus,”
[cited by applicant]
Kaufman, R.J., “Selection and coamplification of heterologous genes in mammalian cells,”
[cited by applicant]
Maniatis, A., et al., “Intermediate-dose melphalan for refractory myeloma,”
[cited by applicant]
Shea, K.J., “Molecular Imprinting of Synthetic Network Polymers: The De Novo synthesis of Macromolecular Binding and Catalytic Sties,”
[cited by applicant]
Colligan, “Production of Monoclonal Antibosies,”
[cited by applicant]
Gal et al., “A true autoactivating enzyme. Structural insight into mannose-binding lectin-associated serine protease-2 activations,”
[cited by applicant]
Thadhani, R., et al., “Acute renal failure,”
[cited by applicant]
Gulla, K.C., et al., “Activation of mannan-binding lectin-associated serine proteases leads to generation of a fibrin clot,”
[cited by applicant]
Kaufman, R. J., “Selection and Coamplification of Heterologous Genes in Mammalian Cells,”
[cited by applicant]
Heja, D., et al., “Revised mechanism of complement lectin-pathway activation revealing the role of serine protease MASP-1 as the exclusive activator of MASP-2,”
[cited by applicant]
Megyeri, M., et al., “Quantitative characterization of the activation steps of mannan-binding lectin (MBL)-associated serine proteases (MASPs) points to the central role of MASP-1 in the initiation of the complement lec…
[cited by applicant]
Yaseen, S., et al., “Lectin pathway effector enzyme mannan-binding lectin-associated serine protease-2 can activate native complement C3 in absence of C4 and/or C2.”
[cited by applicant]
Lee, W.A., “Permeation enhancers for the nasal delivery of protein and peptide therapeutics,”
[cited by applicant]
Gunn, B. M., et al., “Mannose binding lectin is required for alphavirus-induced arthritis/myositis,”
[cited by applicant]
Berger, S. P., et al., “Association between mannose-binding lectin levels and graft survival in kidney transplantation,”
[cited by applicant]
Yoshihiro, I., et al., “An Insulin-Releasing System that is Responsive to Glucose,”
[cited by applicant]
King, L.A., et al., “Propagation, titration and purification of AcMNPV in cell culture,”
[cited by applicant]
Asgari, E., et al., “Mannan-binding lectin-associated serine protease 2 is critical for the development of renal ischemia reperfusion injury and mediates tissue injury in the absence of complement C4,”
[cited by applicant]
Tampe, D., et al., “Potential approaches to reverse or repair renal fibrosis,”
[cited by applicant]
Fearn, A., et al., “The influence of complement activation on chronic renal inflammation and fibrosis,”
[cited by applicant]
Pippin, J. W., et al., “Inducible rodent models of acquired podocyte diseases,”
[cited by applicant]
Pickering, M. C., et al., “C3 glomerulopathy: consensus report,”
[cited by applicant]
Sheerin, N. S., et al., “Synthesis of complement protein C3 in the kidney is an important mediator of local tissue injury,”
[cited by applicant]
Chevalier, R. L., et al., “Ureteral obstruction as a model of renal interstitial fibrosis and obstructive nephropathy,”
[cited by applicant]
Wynn, T. A., “Fibrotic disease and the T(H)1/T(H)2 paradigm,”
[cited by applicant]
Boor, P., et al., “Complement C5 mediates experimental tubulointerstitial fibrosis,”
[cited by applicant]
Abbate, M., et al., “How does proteinuria cause progressive renal damage?”
[cited by applicant]
Mathern, D. R., et al., “Molecules Great and Small: The Complement System,”
[cited by applicant]
Liu et al., “Glomerular mannose-binding lectin deposition is a useful prognostic predictor in immunoglobulin A nephropathy,”
[cited by applicant]
Rensen et al., “Activation of the Complement System in Human Nonalcoholic Fatty Liver Disease,”
[cited by applicant]
Quigg R.J, “Complement and the Kidney,”
[cited by applicant]
Naik A., et al., “Complement regulation in renal disease models,”
[cited by applicant]
Tang, Z., et al., “C3a mediates epithelial-to-mesenchymal transition in proteinuric nephropathy,”
[cited by applicant]
Bao, L., et al., “Distinct roles for C3a and C5a in complement-induced tubulointerstitial injury,”
[cited by applicant]
Gharaee-Kermani, M., et al., “Animal Models of Pulmonary Fibrosis,”
[cited by applicant]
Brown, K. S., et al., “Severe fibrosis in hepatitis C virus-infected patients is associated with increased activity of the mannan-binding lectin (MBL)/MBL-associated serine protease 1 (MASP-1) complex,”
[cited by applicant]
El Saadany, S. A., et al., “Fibrosis severity and mannan-binding lectin (MBL)/MBL-associated serine protease 1 (MASP-1) complex in HCV-infected patients,”
[cited by applicant]
Saeed, A., et al., “Mannan binding lectin-associated serine protease 1 is induced by hepatitis C virus infection and activates human hepatic stellate cells,”
[cited by applicant]
Risdon, R. A., et al., “Relationship between renal function and histological changes found in renal-biopsy specimens from patients with persistent glomerular nephritis,”
[cited by applicant]
Schainuck, L. I., et al., “Structural-functional correlations in renal disease. II. The correlations,”
[cited by applicant]
Nath K.A., “Tubulointerstitial changes as a major determinant in the progression of renal damage,”
[cited by applicant]
Liu, Y., “Cellular and molecular mechanisms of renal fibrosis,”
[cited by applicant]
Duffield, J. S., “Cellular and molecular mechanisms in kidney fibrosis,”
[cited by applicant]
Whittaker, P., et al., “Quantitative assessment of myocardial collagen with picrosirius red staining and circularly polarized light,”
[cited by applicant]
Furness, P. N., et al., “Semiautomatic quantitation of macrophages in human renal biopsy specimens in proteinuric states,”
[cited by applicant]
Yang, H. C., et al., “Models of chronic kidney disease,”
[cited by applicant]
Brunskill, N. J., “Albumin signals the coming of age of proteinuric nephropathy,”
[cited by applicant]
Tryggvason, K., et al., “Causes and consequences of proteinuria: the kidney filtration barrier and progressive renal failure,”
[cited by applicant]
Williams, M. E., “Diabetic nephropathy: the proteinuria hypothesis,”
[cited by applicant]
Baines, R. J., et al., “Tubular toxicity of proteinuria,”
[cited by applicant]
Lozano, R., et al., “Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010,”
[cited by applicant]
Clark, W. F., et al., “Excessive fluid intake as a novel cause of proteinuria,”
[cited by applicant]
Ishola, D. A., Jr., et al., “In mice, proteinuria and renal inflammatory responses to albumin overload are strain-dependent,”
[cited by applicant]
David, S., et al., “Alternative pathway complement activation induces proinflammatory activity in human proximal tubular epithelial cells,”
[cited by applicant]
Lee, V. W., et al., “Adriamycin nephropathy: a model of focal segmental glomerulosclerosis,”
[cited by applicant]
Drawz, P., et al., “Chronic kidney disease,”
[cited by applicant]
Wyatt, R. J., et al., “IgA nephropathy,”
[cited by applicant]
Goto, M., et al., “A scoring system to predict renal outcome in IgA nephropathy: a nationwide 10-year prospective cohort study,”
[cited by applicant]
Berthoux, F., et al., “Predicting the risk for dialysis or death in IgA nephropathy,”
[cited by applicant]
Coppo, R., et al., “Factors predicting progression of IgA nephropathies,”
[cited by applicant]
Reich, H. N., et al., “Remission of proteinuria improves prognosis in IgA nephropathy,”
[cited by applicant]
D'Amico, G., “Natural history of idiopathic IgA nephropathy: role of clinical and histological prognostic factors,”
[cited by applicant]
Matsuda, M., et al., “Deposition of mannan binding protein and mannan binding protein-mediated complement activation in the glomeruli of patients with IgA nephropathy,”
[cited by applicant]
Liu, L. L., et al., “Urinary mannose-binding lectin is a biomarker for predicting the progression of immunoglobulin (Ig)A nephropathy,”
[cited by applicant]
KDIGO, “KDIGO Clinical Practice Guideline for Glomerulonephritis,”
[cited by applicant]
Harlow, E., Antibodies, A Laboratory Manual. 1988, pp. 37-59.
[cited by applicant]
Kerr, H., et al., “Comlement-mediated injury and protection of endothelium: Lessons from atypical haemolytic uraemic syndrome,”
[cited by applicant]
Sato, Y., et al., “Pulmonary tumor thrombotic microangiopathy,”
[cited by applicant]
Dobó, J., et al., “Be on target: Strategies of targeting alternative and lectin pathway components in complement-mediated diseases,”
[cited by applicant]
Hui, D.S., et al., “The continuing 2019-nCoV epidemic threat of novel coronaviruses to global health—The latest 2019 novel coronavirus outbreak in Wuhan, China,”
[cited by applicant]
Hilleman, M.R., et al., “Realities and enigmas of human viral influenza: pathogenesis, epidemiology and control,”
[cited by applicant]
Su, S., et al., “Novel influenza D virus: Epidemiology, pathology, evolution and biological characteristics,”
[cited by applicant]
Fouchier, R.A., et al., “Avian influenza A virus (H7N7) associated with human conjunctivitis and a fatal case of acute respiratory distress syndrome,”
[cited by applicant]
World Health Organization, Weekly epidemiological record, Nov. 14, 2008, 83
[cited by applicant]
Eccles, R., “Understanding the symptoms of the common cold and influenza,”
[cited by applicant]
Schmitz, N., et al., “Interleukin-1 is responsible for acute lung immunopathology but increases survival of respiratory influenza virus infection,”
[cited by applicant]
Cheung, C.Y., et al., “Induction of proinflammatory cytokines in human macrophaegs by Influenza A (H5N1) viruses: a mechanism for the unusual severity of human disease?”
[cited by applicant]
Kash, J.C., et al., “Genomic analysis of increased host immune and cell death responses induced by 1918 influenza virus,”
[cited by applicant]
Berge, S.M., et al., “Pharmaceutical salts,”
[cited by applicant]
Pétursson, S., “Protecting groups in carbohydrate chemistry,”
[cited by applicant]
Janeway, C.A., et al., “The interaction of the antibody molecule with specific antigen”, 3.6-3.9 (pp. 1-5), in Immunobilogy: The Immune System in Health and Disease, 5
[cited by applicant]
Szymanski, L.J., et al., “Coronary artery aneurysms and thrombosis in Kawasaki disease,”
[cited by applicant]
Hauang, M.-J., et al., “Impact of acute kidney injury on coagulation in adult minimal change nephropathy,”
[cited by applicant]
Rota, P.A., et al., “Characterization of a novel coronavirus associated with severe acute respiratory syndrome,”
[cited by applicant]
Zaki, A.M., et al., “Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia,”
[cited by applicant]
World Health Organization, Novel Coronavirus(2019-nCoV), Siutation Report-22. Data as reported by Feb. 11, 2020.
[cited by applicant]
Guan, W., et al., “Clinical characteristics of coronavirus disease 2019 in China,”
[cited by applicant]
Gralinski, L.E., et al., “Complement activation contributes to severe acute respiratory syndrome coronavirus pathogenesis,”
[cited by applicant]
Hui, D.S., et al., “The 1-year impact of sever acute respiratory syndrome on pulmonary function, exercise capacity, and quality of life in a cohort of survivors,”
[cited by applicant]
Gross, T.J., et al., “Idiopathic pulmonary fibrosis,” NEJM 345(7):517-525 (2001).
[cited by applicant]
World Health Organiation, WHO Director-General's opening remarks at the media briefing on Covid-19—Mar. 3, 2020.
[cited by applicant]
Sweeny, R.M., et al., “Acute respiratory distress syndrome,”
[cited by applicant]
The ARDS Definition Task Force, “Acute respiratory distress syndrome,”
[cited by applicant]
Zhou, F., et al., “Clinical course and risk factors for mortality of adult inpatients with Covid-19 in Wuhan, China: a retrospective cohort study,”
[cited by applicant]
Remuzzi, A., et al., “Covid-19 and Italy: what next?”
[cited by applicant]
Wichmann, D., et al., “Autopsy findings and venous thromboembolism in patients with Covid-19,”
[cited by applicant]
Xu, Z., et al., “Pathological finding of Covid-19 associated with acute respiratory distress syndrome,”
[cited by applicant]
Horby, P.W., et al., “Effect of dexamethasone in hospitalized patients with Covid-19—Preliminary Report,”
[cited by applicant]
Gritti, G., et a., “IL-6 signalling pathway inactivation with siltuximab in patients with Covid-19 respiratory failure: an observational cohort study,”
[cited by applicant]
Magro, C., et al., “Complement associated microvascular injury and thrombosis in the pathogenesis of severe Covid-19 infection: A report of five cases,”
[cited by applicant]
Sun, S., et al., “Inhibition of complement activation alleviates acute ling injury induced by highly pathogenic avian influenza H5N1 virus infection,”
[cited by applicant]
Garcia Suquia, A., et al.,“High D-dimer levels after stopping anticoagulants in pulmonary embolism with sleep apnoea,”
[cited by applicant]
Varga, Z., et al., “Endotheial cell infection and endotheliitis in Covid-19,”
[cited by applicant]
Ackermann, M., et al., Pulmonary vascular endothelialitis, thrombosis, and engiogenesis in Covid-19,
[cited by applicant]
Green, S.J., “Covid-19 accelerates endothelial dysfuction and nitric oxide,”
[cited by applicant]
Teuwen, L.-A., at al., “Covid-19: the vasculature unleashed,”
[cited by applicant]
Goshua, G., et al., “Endotheliopathy in Covid-19-associated coagulopathy: evidence from a single-centre, cross-sectional study,”
[cited by applicant]
Jaramillo-Rocha, V., “Acute respiratory distress syndrome,”
[cited by applicant]
Ferguson, N.D., et al., “The Berlin definition of ARDS: an expanded rationale, justification, and supplementary material,”
[cited by applicant]
Fagiuoli, S., et al., “Adaptations and lessons in the province of Bergamo,”
[cited by applicant]
Corman, V.M., et al., “Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR,”
[cited by applicant]
Farinacci, M., et al., “Circulating endothelial cells as biomarker for cardiovascular diseases,”
[cited by applicant]
Moussa, M.D., et al., “Evaluation of endothelial damage in sepsis-related ARDS using circulating endothelial cells,”
[cited by applicant]
Almici, C., et al., “Circulating endothelial cell count: a reliable marker of endothelial damage in patients undergoing hematopoietic stem cell transplantation,”
[cited by applicant]
Thompson, B.T., et al., “Acute respiratory distress syndrome,”
[cited by applicant]
Gao, T., et al., “Highly pathogenic coronavirus N protein aggravates lung injury by MASP-2-mediated complement over-activation,”
[cited by applicant]
Xiong, Y., et al., “Transscriptomic characterists of bronchoalveolar lavage fluid and peripheral blood mononuclear cells in Covid-19 patients,”
[cited by applicant]
Mastaglio, S. et al., “The first case of Covid-19 treated with the complement C3 inhibitor AMY-101,”
[cited by applicant]
Diurno, F., et al., “Eculizumab treatment in patients with Covid-19: preliminary results from real life ASL Napoli 2 Nord experience,”
[cited by applicant]
Veronese, N., et al., “Use of corticosteroids in cornovirus disease 2019 pneumonia: a systematic review of the literature,”
[cited by applicant]
Marshall, M., “Covid-19's lasting misery,”
[cited by applicant]
Troyer, E.A., et al., “Are we facing a crashing wave of neuropsychiatric sequelae of Covid-19? Neuropsychiatric symptoms and potential immunologic mechanisms,”
[cited by applicant]
Babapoor-Farrokhran, S., et al., “Myocardiol injury and Covid-19: Possible mechanisms,”
[cited by applicant]
Heneka, M.T., et al., “Immediate and long-term consequences of Covid-19 infections for the development of neurological disease,”
[cited by applicant]
Yelin, D, et al., “Long-term consequences of Covid-19: research needs,”
[cited by applicant]
Diorio, C., et al., “Evidence of thrombotic microangiopathy in children with SARS-CoV-2 across the spectrum of clinical presentations,”
[cited by applicant]
Radia, T., et al., “Multi-system inflammatory syndrome in children & adolescents (MIS-C): A systemic review of clinical features and presentation,”
[cited by applicant]
Bonow. R.O., et al., “Association of Coronavirus Disease 2019 (Covid-19) with Myocardial Injury and Mortality,”
[cited by applicant]
Del Rio, C., et al., “Long-term health consequences of Covid-19,”
[cited by applicant]
Marchiano, S., et al., “SARS-CoV-2 infects human pluripotent stem cell-derived cardiomyocytes, impairing electrical and mechanical function,”
[cited by applicant]
Puntmann, V.O., et al., “Outcomes of cardiovascular magnetic resonance imaging in patient recently recovered from coronavirus disease 2019 (Covid-19),”
[cited by applicant]
Lindner, D., et al., “Associateion of cardiac infection with SARS-CoV-2 in confirmed Covid-19 autopsy cases,”
[cited by applicant]
Chen, X., et al., “Detectable serum SARS-CoV-2 viral load (RNAeamia) isclosely associated with drastically elevated interleukin 6 (IL-6) level in critically Covid-19 patients,”
[cited by applicant]
Beltrame, M.H., et al., “MBL-associated serine proteases (MASPs) and infectious diseases,”
[cited by applicant]
Rambaldi, A., et al., “Endothelial injury and thrombotic microangiopathy in Covid-19: Treatment with the lectin-pathway inhibitor Narsoplimab,”
[cited by applicant]
Szakacs, D., et al., “Novel MASP-2 inhibitors developed via directed evolution of human TFPI1 are potent lectin pathway inhibitors,”
[cited by applicant]
Liu, et al., “Clinical features and progression of acute respiratory distress syndrome in coronavirus disease 2019,”
[cited by applicant]
Campbell, C. M., et al., “Will complement inhibition be the new target in treating Covid-19-elated systemic thrombosis?”,
[cited by applicant]
Pandya, P. H., et al., “Complement system in lung disease.”
[cited by applicant]